by What is the Genitourinary Syndrome of Menopause (GSM) Market Size in 2026?
The global genitourinary syndrome of menopause (GSM) market size was calculated at USD 1.60 billion in 2025 and is predicted to increase from USD 1.72 billion in 2026 to approximately USD 3.21 billion by 2035, expanding at a CAGR of 7.20% from 2026 to 2035. The genitourinary syndrome of menopause (GSM) market is growing due to rising awareness of menopausal health and wider availability of therapies.
Key Takeaways
- North America dominated the genitourinary syndrome of menopause (GSM) market in 2025, with 36.70% share.
- Asia-Pacific is expected to be the fastest-growing region between 2026 and 2035.
- By treatment type, vaginal estrogen therapies segment registered its dominance over the global market with a share of 38.60% in 2025.
- By treatment type, the energy-based devices and procedures segment is expected to witness the fastest growth in the market over
- the forecast period.
- By delivery modality, the prescription therapies segment held a dominant position in the market with a share of 56.70% in 2025.
- By delivery modality, the device-based procedures segment is expected to grow at the fastest CAGR during the forecast period.
- By indication, the vaginal dryness and irritation segment dominated the market with a share of 34.60% in 2025.
- By indication, the urinary symptoms segment is expected to show the fastest growth over the forecast period.
- By distribution channel, the retail pharmacy segment led the global market with a share of 44.60% in 2025.
- By distribution channel, the online pharmacy and e-commerce segment is expected to witness the fastest growth in the market over the forecast period.
- By end user, the hospitals segment registered its dominance over the global genitourinary syndrome of menopause (GSM) market with a share of 46.80% in 2025.
- By end user, the home care and self-care segment is expected to expand rapidly in the market in the coming years.
Genitourinary Syndrome of Menopause (GSM) Market Overview
The genitourinary syndrome of menopause (GSM) market covers products and procedures used to manage chronic vulvovaginal and lower urinary tract symptoms associated with estrogen decline after menopause. It includes prescription therapies such as local vaginal estrogens, oral SERMs, and vaginal DHEA, along with OTC moisturisers and lubricants, plus energy-based device procedures offered in women’s health clinics. Market revenues span product sales, dispensing channels, and procedural service delivery across hospitals, clinics, and self-care settings.
What is the Role of AI in the Market?
Artificial intelligence is changing the genitourinary syndrome of menopause (GSM) market. AI helps to analyze large amounts of data to predict personalized treatment. Machine learning models, such as telehealth tools and tracking apps, identify abnormal signs, which facilitate early detection and treatment. In pharmaceutical research, AI-powered tools can help scientists to review clinical results more efficiently
What are the Market Trends?
- The genitourinary syndrome of menopause (GSM) market is influenced by rising research and drug development by pharmaceutical companies to develop innovative therapies for GSM and related menopausal conditions.
- Rising awareness of menopause-related health issues by healthcare campaigns, educational programs, and digital health platform are gaining attention to genitourinary syndrome of menopause.
- Patients and healthcare professionals prefer non-hormonal therapies like selective local vaginal estrogens, oral SERMs, and vaginal DHEA, along with OTC moisturisers that relieve symptoms without systemic hormonal exposure.
- The growing population of postmenopausal women is influencing the market.
Genitourinary Syndrome of Menopause (GSM) Market Regional Insights
North America Genitourinary Syndrome of Menopause (GSM) Market Size and Growth 2026 to 2035
The North America genitourinary syndrome of menopause (GSM) market size is estimated at USD 587.20 million in 2025 and is projected to reach approximately USD 1,187.70 million by 2035, with a 7.30% CAGR from 2026 to 2035.
What Factors Made the North America Region the Dominant Region in the Market?
North America dominated the global genitourinary syndrome of menopause (GSM) market in 2025, with 36.70% share due to high awareness of menopause and related health concerns. Many women are comfortable seeking medical advice when suffering from symptoms such as dryness, irritation, or urinary discomfort. The government is the region, and the regulatory framework is encouraging and approving new and advanced hormone-free drugs to treat genitourinary syndrome of menopause.
U.S. Genitourinary Syndrome of Menopause (GSM) Market Size and Growth 2026 to 2035
The U.S. genitourinary syndrome of menopause (GSM) market size is calculated at USD 440.40 million in 2025 and is expected to reach nearly USD 896.71 million in 2035, accelerating at a strong CAGR of 7.37% between 2026 and 2035.
U.S. Market Trends
The U.S genitourinary syndrome of menopause (GSM) market is witnessing strong growth driven by high healthcare spending and widespread availability of advanced interventional devices and treatments. The hospitals, women’s health clinics, and private practices provide guidance and treatment options for genitourinary syndrome of menopause. The growing emphasis on personalized medicine. Early diagnosis and treatment, and rapid adoption of healthcare apps for online consultations, made the country dominate the market.
Which Factors Influence the Fastest Growth of the Asia Pacific Market?
Asia Pacific is expected to grow at the fastest CAGR in the genitourinary syndrome of menopause (GSM) market during the forecast period. Before, women considered these symptoms as normal because discussions about menopause were considered private. The healthcare education and improving access to gynaecological services help women to seek medical consultation. The healthcare infrastructure is improving, and pharmacies and online platforms are also expanding access to supportive medication for treatment. These factors contribute to the growth of the country in the market.
India Market Trends
India is one of the most important markets in the region due to its large population and rising awareness of menopausal health. The gynaecologists and healthcare organizations are spreading awareness about menopausal health, which leads to an increase in the diagnosis rate. The rise of online pharmacies like 1mg and PharmEasy has made treatment more accessible.
Genitourinary Syndrome of Menopause (GSM) Market Value Chain Analysis
Genitourinary Syndrome of Menopause (GSM) Market Companies
- Pfizer
- AbbVie
- Shionogi
- Novo Nordisk
- Mayne Pharma
- Teva Pharmaceutical Industries
- DEKA
- Church and Dwight
- Reckitt
- Haleon
- Bayer
- Viatris
- Organon
- Besins Healthcare
- CooperSurgical
Recent Developments
- In February 2026, IBSA UK launched Hyaluxelle, a non-hormonal injectable hyaluronic acid treatment for adult women suffering from atrophic symptoms affecting the vulvar vestibule and genitourinary syndrome of menopause.(Source: https://www.businesscheshire.co.uk )
- In April 2025, the American Urological Association (AUA), along with SUFU and AUGS, released the 2025 Guideline on Genitourinary Syndrome of Menopause (GSM), outlining evidence-based practices for evaluating and treating symptoms like dryness, dyspareunia, and urinary issues. The guideline promotes shared decision-making, covering both hormonal and non-hormonal therapies.(Source: https://www.auanet.org )
Segments Covered in the Report
By Treatment Type
- Vaginal estrogen therapies
- Oral SERM therapies
- Vaginal DHEA therapies
- Non-hormonal moisturisers and lubricants
- Energy-based devices and procedures
By Delivery Modality
- Prescription therapies
- OTC therapies
- Device-based procedures
By Indication Focus
- Vaginal dryness and irritation
- Dyspareunia
- Urinary symptoms
- Mixed GSM symptom management
By Distribution Channel
- Retail pharmacy
- Hospital pharmacy
- Online pharmacy and e-commerce
- Specialty pharmacy
By End User
- Hospitals
- Gynaecology and women’s health clinics
- Ambulatory surgical centres
- Home care and self-care
By Region
- North America
- Latin America
- Europe
- Asia-pacific
- Middle and East Africa
Also Check this Report: Real-Time Decision-Making AI Agents Market
Get Sample : https://www.precedenceresearch.com/sample/8115
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
